Corrigendum.

Abstract

ImmunologyVolume 159, Issue 2 p. 242-242 CorrigendumFree Access Corrigendum This article corrects the following: CD6 monoclonal antibodies differ in epitope, kinetics and mechanism of action Lee I. Garner, Andrew Hartland, Johannes Breuning, Marion H. Brown, Volume 155Issue 2Immunology pages: 273-282 First Published online: June 13, 2018 First published: 14 November 2019 https://doi.org/10.1111/imm.13113AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat The article1 should be read with reference to new data2 for the correct specificity of the CD6 mAbs, OX124, OX125 and OX126.3, 4 Domain specificity for OX124, OX125 and OX126 should be deleted and the name of the antibody given. As the focus of the article is domain 1 mAbs, the overall conclusions are not altered. Specific alterations to the text are: Summary, p273. CD6 domain 1, OX125 and OX126 mAbs were equally effective in triggering interleukin-2 production…….CD6 domain 1 mAbs hindered binding of multivalent immobilised CD166 but were inferior compared with blocking by soluble CD166 or another CD6 mAb. Introduction, p274. Immunisation with soluble recombinant CD6 led to the production of novel CD6 mAbs(6). Materials and Methods, Monoclonal antibodies, p274. CD6, OX124 (mouse IgG1), OX125 (mouse IgG2b) and OX126 (mouse IgG1)(6) Materials and Methods, Flow cytometry, p275. CD6 mAb (OX126) Results, p277 and Figure 3. CD6 domain 1, OX125 and OX126 mAbs….. Results, p278. …CD6 mAbs, OX124, OX125 and OX126 specific for different epitopes on CD6 for efficacy …a CD6 mAb, OX125… interfere with OX126 binding to CD6. We began by asking do CD6 domain 1 mAbs hinder binding of OX126(6)……interactions of OX126. Results, p279 and Figure 4. CD6 mAb, OX126. Results, p279 and Figure 5. The data (Figure 5) are inconsistent with the specificity of OX1262 and indicate an antibody labelling error.3, 4 Read: CD6 domain 1 mAbs are less effective compared with another CD6 mAb….another CD6 mAb which was superior….another CD6 mAb was more effective >UMCD6>itolizumab at Discussion, p280. binding to domain 1 and by OX125 or OX126 in the efficacy of triggering.. Discussion, p281…competition experiment with a CD6 mAb, OX126..Delete text: “As none …soluble CD166(6)”. UMCD6 is not as efficacious at blocking CD6/CD166 interactions compared with another CD6 mAb References 1Garner LI, Hartland A, Breuning J, Brown MH. CD6 monoclonal antibodies differ in epitope, kinetics and mechanism of action. Immunology 2018; 155: 273– 82. 2Santos RF, Oliveira L, Brown MH, Carmo AM. Domain-specific CD6 monoclonal antibodies identify CD6 isoforms generated by alternative-splicing. Immunology 2019; 155: 273– 82. 3Hassan NJ, Simmonds SJ, Clarkson NG, Hanrahan S, Puklavec MJ, Bomb M et al. Second correction for Hassan et al., CD6 regulates T-cell responses through activation-dependent recruitment of the positive regulator SLP-76. Mol Cell Biol 2019; 39: e00054- 19. 4Hassan NJ, Simmonds SJ, Clarkson NG, Hanrahan S, Puklavec MJ, Bomb M et al. CD6 regulates T-cell responses through activation-dependent recruitment of the positive regulator SLP-76. Mol Cell Biol 2006; 26: 6727– 38. Volume159, Issue2February 2020Pages 242-242 ReferencesRelatedInformation